FDA approves first oral small‑molecule treatment RebiQuent for moderate to severe atopic dermatitis in adults
The U.S. Food and Drug Administration has not approved a drug called RebiQuent for moderate to severe atopic dermatitis in adults, according to official FDA records as of June 2024. Current FDA-approved oral small-molecule treatments for this condition include abrocitinib and upadacitinib, both Janus kinase inhibitors approved in January 2022.
The FDA has not approved a drug called RebiQuent for moderate to severe atopic dermatitis in adults, according to official FDA databases, press releases, and safety communications reviewed through June 2024. Current FDA-approved oral small-molecule treatments for this condition include abrocitinib and upadacitinib, both oral Janus kinase (JAK) inhibitors that received approval in January 2022, according to the U.S. Food and Drug Administration and a 2022 Washington State Health Care Authority evidence review.
Clinical trials demonstrated that 47.5% of patients taking 200 mg of abrocitinib daily achieved an Investigator’s Global Assessment (IGA) score of 0 or 1, indicating clear or almost clear skin, at 12 weeks, compared with 32.0% of patients on 100 mg.
Abrocitinib is indicated for adults 18 years and older with moderate to severe atopic dermatitis who have not responded to other systemic therapies or for whom such treatments are not advisable. Upadacitinib showed even higher efficacy, with 60 to 70% of participants achieving at least a 75% improvement in the Eczema Area and Severity Index (EASI-75) by weeks 12 to 16, compared with 29 to 40% for abrocitinib and baricitinib, the latter of which was still under investigation at the time of the 2022 review.
The Washington State Health Care Authority report, published in 2022, identified abrocitinib and upadacitinib as FDA-approved oral JAK inhibitors for atopic dermatitis, while baricitinib remained under study. The report characterized these newer therapies as expanding treatment options beyond traditional systemic immunosuppressants but noted the importance of monitoring for safety concerns, including serious infections and thrombosis, which are associated with JAK inhibitors as a class.
No FDA or major regulatory, clinical, or manufacturer sources have documented approval of RebiQuent as a treatment for atopic dermatitis. Searches of FDA records, PubMed, and dermatology society communications yielded no references to RebiQuent as an approved product name or as a brand or generic equivalent of abrocitinib, upadacitinib, baricitinib, or other oral treatments for atopic dermatitis. Peer-reviewed literature describes abrocitinib explicitly as a “recently FDA-approved” oral JAK-1 inhibitor for adult patients with moderate to severe disease, confirming that oral small-molecule treatments in this class have been available since early 2022.
In addition to oral small molecules, biologic therapies such as dupilumab (Dupixent) have been FDA-approved for adults with moderate to severe atopic dermatitis who cannot use or have failed topical corticosteroids. Approved under Priority Review and Breakthrough Therapy designations, dupilumab demonstrated significant efficacy in clinical trials, with patients achieving clear or almost clear skin and reduced itch after 16 weeks. Other biologics recently approved or under investigation include lebrikizumab, nemolizumab, and tralokinumab, according to the Washington State review.
Traditional systemic treatments such as cyclosporine, methotrexate, azathioprine, and mycophenolate mofetil remain options for severe cases but carry risks of broad immunosuppression and side effects. Newer targeted therapies aim to reduce these risks by selectively modulating disease pathways.
Topical treatments have also seen recent FDA approvals. In July 2024, the FDA approved ZORYVE (roflumilast) cream 0.15% for mild to moderate atopic dermatitis in adults and children aged six years and older. This once-daily, steroid-free topical phosphodiesterase-4 inhibitor is indicated for long-term disease control and rapid itch reduction. Clinical data report common adverse reactions including headache (2.9%), nausea (1.9%), application-site pain (1.5%), diarrhea (1.5%), and vomiting (1.5%). The manufacturer is also evaluating a lower 0.05% strength of roflumilast cream for children aged 2 to 5 years.
Head-to-head trials have shown that abrocitinib 200 mg once daily provides greater improvements in disease severity and itch response at 12 weeks compared with dupilumab administered subcutaneously every other week. Most adverse events reported with abrocitinib were described as not severe and self-limited, consistent with selective JAK-1 inhibition, although JAK inhibitors carry class warnings for serious infections, thrombosis, and laboratory abnormalities.
The 2022 Washington State Health Care Authority report emphasized the role of newer therapies, including oral JAK inhibitors and biologics, in improving disease severity scores and quality of life relative to older treatments. It also noted the need to balance efficacy with safety and long-term risks associated with these agents. Topical JAK inhibitors such as ruxolitinib have also been FDA-approved as non-systemic alternatives, showing high response rates in clinical studies.
Overall, official records and peer-reviewed sources confirm that oral small-molecule treatments for moderate to severe atopic dermatitis in adults have been FDA-approved since January 2022, with no evidence supporting the approval of a drug named RebiQuent.
